



FDA Authorizes Study Protocol for New Mode of Administration for Trogarzo®

March 4, 2019

Theratechnologies Inc. (Theratechnologies) (TSX: TH) has been informed by its partner, TaiMed Biologics Inc. that the Food and Drug Administration has authorized TMB-302, the study protocol to evaluate an intravenous (IV) slow push formulation of Trogarzo® (ibalizumab-uiyk) injection.